22 May 2007, London, UK: Ark Therapeutics Group plc announces today that it has been given clearance by the US Recombinant DNA Advisory Committee (RAC) for its planned Phase III US clinical study of Trinam(R), Ark’s novel gene-based therapy to prevent haemodialysis access graft blockage.
